NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in September: September 8-10: H.C. Wainwright 27th Annual Global Investment Conference. Jason Tardio, President and Chief Operating Officer of Immunic, will present a company overview. The on-demand presen ...